Filtering





DOP81: Quality improvement by semi-automated benchmarking of a core outcome quality indicator set in Inflammatory Bowel Disease: A multicentric feasibility studyECCO'21 Virtual
Year: 2021
Authors: Bossuyt, P.(1);Baert, D.(2);Baert, F.(3);Hoefkens, E.(1);Huys, I.(2);Lembrechts, N.(1);De Jonckere, E.(3);Dewint, P.(2);Pouillon, L.(1)
(1)Imelda General Hospital Bonheiden, Department of Gastroenterology, Bonheiden, Belgium;(2)AZ Maria Middelares, Gastroenterology, Gent, Belgium;(3)AZ Delta, Gastroenterology, Rumbeke, Belgium
DOP82: Corticosteroid-free remission of Ulcerative Colitis with filgotinib maintenance therapy: Post hoc analysis of the phase 2b/3 SELECTION studyECCO'21 Virtual
Year: 2021
Authors: Loftus- Jr, E.(1);Vermeire, S.(2);Feagan, B.(3);Yun, C.(4);Hsieh, J.(4);Liu, X.(4);Zhao, S.(4);Moerch, U.(5);Sandborn, W.J.(6);Hibi, T.(7)
(1)Mayo Clinic, Department of Internal Medicine- Department of Gastroenterology and Hepatology, Rochester- MN, United States;(2)University Hospitals Leuven, Department of Gastroenterology, Leuven, Belgium;(3)Western University, Department of Medicine- Division of Gastroenterology, London- ON, Canada;(4)Gilead Sciences, Inc., Foster City, United States;(5)Gilead Sciences, Inc., Copenhagen, Denmark;(6)University of California, Department of Medicine, San Diego- La Jolla- CA, United States;(7)Kitasato Institute Hospital- Kitasato University, Center for Advanced IBD Research and Treatment, Tokyo, Japan
DOP83: Efficacy and Safety of Ustekinumab for Ulcerative Colitis Through 3 Years: UNIFI Long-term ExtensionECCO'21 Virtual
Year: 2021
Authors: Abreu, M.T.(1);Danese, S.(2);Sandborn, W.J.(3);Miao, Y.(4);Tikhonov, I.(4);Zhang, H.(4);Panaccione, R.(5);Hisamatsu, T.(6);Scherl, E.J.(7);Leong, R.W.(8);Rowbotham, D.S.(9);Arasaradnam, R.P.(10);Afif, W.(11);Peyrin-Biroulet, L.(12);Sands, B.E.(13);Marano, C.(4)
(1)University of Miami Miller School of Medicine, Department of Medicine, Miami, United States;(2)Istituto Clinico Humanitas, Department of Gastroenterology, Milano, Italy;(3)University of California San Diego, Division of Gastroenterology, San Diego, United States;(4)Janssen Research & Development- LLC., Immunology, Spring House, United States;(5)University of Calgary, Inflammatory Bowel Disease Unit, Calgary, Canada;(6)Kyorin University School of Medicine, Third Department of Internal Medicine, Tokyo, Japan;(7)New York Presbyterian Weill Cornell Medical College, Roberts Center for Inflammatory Bowel Disease, New York, United States;(8)Concord Repatriation General Hospital, Inflammatory Bowel Disease Clinic, Concord, Australia;(9)Auckland City Hospital, Gastroenterology, Auckland, New Zealand;(10)University Hospital Coventry & Warwickshire, GI Medicine, Coventry, United Kingdom;(11)McGill University Health Center, Division of Gastroenterology, Montreal, Canada;(12)Nancy University Hospital- Université de Lorraine, Department of Gastroenterology, Nancy, France;(13)Mount Sinai School of Medicine, Henry D. Janowitz Division of Gastroenterology, New York, United States
DOP84: Early treatment responses within 14 days of intravenous vedolizumab induction therapy for Crohn’s Disease: Post hoc analysis of patient-reported outcomes from the VISIBLE 2 studyECCO'21 Virtual
Year: 2021
Authors: D'Haens, G.(1);Baert, F.(2);Danese, S.(3);Kobayashi, T.(4);Loftus Jr., E.V.(5);Sandborn, W.J.(6);Dornic, Q.(7);Lindner, D.(7);Kisfalvi, K.(8);Marins, E.G.(8);Vermeire, S.(9)
(1)Amsterdam University Medical Centers, Department of Gastroenterology, Amsterdam, The Netherlands;(2)AZ Delta, Department of Gastroenterology, Roeselare, Belgium;(3)Humanitas University, Department of Gastroenterology, Milan, Italy;(4)Kitasato University Kitasato Institute Hospital, Center for Advanced IBD Research and Treatment, Tokyo, Japan;(5)Mayo Clinic College of Medicine, Division of Gastroenterology and Hepatology, Rochester, United States;(6)University of California San Diego, Department of Medicine, San Diego, United States;(7)Takeda, Statistical and Quantitative Science, Zurich, Switzerland;(8)Takeda, Global Medical Affairs, Cambridge, United States;(9)University Hospitals Leuven, Department of Gastroenterology and Hepatology, Leuven, Belgium
DOP85: Corticosteroid-free efficacy and safety outcomes in patients receiving tofacitinib in the OCTAVE Sustain maintenance studyECCO'21 Virtual
Year: 2021
Authors: Vavricka, S.R.(1);Greuter, T.(2);Cohen, B.L.(3);Reinisch, W.(4);Steinwurz, F.(5);Fellmann, M.(6);Guo, X.(7);Lawendy, N.(7);Paulissen, J.(8);Peyrin-Biroulet, L.(9)
(1)Department of Gastroenterology and Hepatology- University Hospital Zurich, and Center for Gastroenterology and Hepatology, Zürich, Switzerland;(2)Department of Gastroenterology and Hepatology, University Hospital Zürich, Zürich, Switzerland;(3)Department of Gastroenterology- Hepatology- and Nutrition, Digestive Disease and Surgery Institute- Cleveland Clinic, Cleveland- Ohio, United States;(4)-, Medical University of Vienna, Vienna, Austria;(5)Unit of Inflammatory Bowel Disease, Hospital Israelita Albert Einstein, São Paulo, Brazil;(6)Pfizer Switzerland AG, Zürich, Switzerland;(7)Pfizer Inc, Collegeville, Pennsylvania, United States;(8)Pfizer Inc, New York, New York, United States;(9)Department of Gastroenterology, Inserm U1256 NGERE- Nancy University Hospital- Université de Lorraine, Vandœuvre-lès-Nancy, France
DOP86: Corticosteroid-sparing effects of ustekinumab therapy for Ulcerative Colitis through 3 years: UNIFI long-term extensionECCO'21 Virtual
Year: 2021
Authors: Scherl, E.J.(1);Rowbotham, D.S.(2);Danese, S.(3);Sandborn, W.J.(4);Miao, Y.(5);Zhang, H.(5);Abreu, M.T.(6);Panaccione, R.(7);Afif, W.(8);Hisamatsu, T.(9);Leong, R.W.(10);Arasaradnam, R.P.(11);Sands, B.E.(12);Marano, C.(5)
(1)New York Presbyterian Weill Cornell Medical College, Roberts Center for Inflammatory Bowel Disease, New York, United States;(2)Auckland City Hospital, Gastroenterology, Auckland, New Zealand;(3)Instituto Clinico Humanitas, Department of Gastroenterology, Milano, Italy;(4)University of California San Diego, Division of Gastroenterology, La Jolla, United States;(5)Janssen Research & Development- LLC, Immunology, Spring House, United States;(6)University of Miami Miller School of Medicine, Department of Medicine, Miami, United States;(7)University of Calgary, Inflammatory Bowel Disease Unit, Calgary, Canada;(8)McGill University Health Centre, Division of Gastroenterology, Montreal, Canada;(9)Kyorin University School of Medicine, Third Department of Internal Medicine, Tokyo, Japan;(10)Concord Repatriation General Hospital, Inflammatory Bowel Disease Clinic, New South Wales, Australia;(11)University Hospital Coventry and Warwickshire, Gastrointestinal Medicine, Coventry, United Kingdom;(12)Mount Sinai School of Medicine, Henry D. Janowitz Division of Gastroenterology, New York, United States UNIFI
DOP87: Disease clearance as a new therapeutic target in patients with Ulcerative Colitis: A multicenter retrospective cohort studyECCO'21 Virtual
Year: 2021
Authors: D'Amico, F.(1);Fiorino, G.(1);Massarini, E.(1);Solitano, V.(1);Guillo, L.(2);Allocca, M.(1);Furfaro, F.(3);Zilli, A.(3);Bonovas, S.(1);Peyrin-Biroulet, L.(4);Danese, S.(5)
(1)Humanitas University, Department of Biomedical Sciences, Milan, Italy;(2)University Hospital of Nancy- Unicersity of Lorraine, Department of Gastroenterology and Inserm NGERE U1256, Vandoeuvre-lès-Nancy, France;(3)Humanitas Research Hospital- IRCCS, IBD center, Milan, Italy;(4)University Hospital of Nancy- University of Lorraine, Department of Gastroenterology and Inserm NGERE U1256, Vandoeuvre-lès-Nancy, France;(5)IRCCS Humanitas Research Hospital, Department of Gastroenterology, Rozzano, Italy
DOP88: Effect of risankizumab on patient-reported outcomes in patients with Crohn’s Disease who had an inadequate response or intolerance to conventional and/or biologic treatments: Results from phase 3 MOTIVATE and ADVANCE trialsECCO'21 Virtual
Year: 2021
Authors: Peyrin-Biroulet, L.(1);Louis, E.(2);Ghosh, S.(3);Lee, S.D.(4);Griffith, J.(5);Wallace, K.(5);Berg, S.(5);Loftus Jr, E.V.(6)
(1)University Hospital of Nancy- Lorraine University, Gastroenterology, Vandoeuvre, France;(2)University Hospital CHU of Liège, Gastroenterology, Liège, Belgium;(3)University of Birmingham, Institute of Translational Medicine, Birmingham, United Kingdom;(4)University of Washington, Department of Medicine- Division of Gastroenterology, Seattle, United States;(5)AbbVie Inc., Health Economics and Outcomes Research, North Chicago, United States;(6)Mayo Clinic, Division of Gastroenterology and Hepatology, Rochester, United States
DOP89: Effects of ferric derisomaltose and ferric carboxymaltose on hypophosphatemia in iron-deficiency anaemia due to Inflammatory Bowel Disease: A Phase IV randomised clinical trialECCO'21 Virtual
Year: 2021
Authors: Zoller, H.(1);Wolf, M.(2);Blumenstein, I.(3);Primas, C.(4);Lindgren, S.(5);Thomsen, L.L.(6);Reinisch, W.(4);Iqbal, T.(7)
(1)Medical University of Innsbruck, Christian Doppler Laboratory of Iron and Phosphate Biology- Department of Medicine I, Innsbruck, Austria;(2)Duke University School of Medicine, Medicine – Nephrology, Durham- NC, United States;(3)University Hospital Frankfurt, Department of Internal Medicine 1, Frankfurt, Germany;(4)Medical University of Vienna, Department of Internal Medicine III, Vienna, Austria;(5)Clinical Sciences Malmö- Lund University- Sweden, Gastroenterology- Skane University Hospital, Lund, Sweden;(6)Pharmacosmos A/S, Clinical Research & Development, Holbæk, Denmark;(7)Queen Elizabeth Hospital Birmingham, Department of Gastroenterology, Birmingham, United Kingdom
DOP90: Physician global assessment of IBD Activity is associated with COVID-19 severity in patients aged less than 50 yearsECCO'21 Virtual
Year: 2021
Authors: Ricciuto, A.(1);Lamb, C.(2,3);Benchimol, E.I.(1);Walker, G.(4);Kennedy, N.(5,6);Kuenzig, M.E.(1);Kaplan, G.(7);Griffiths, A.M.(1);Reinisch, W.(8);Sebastian, S.(9,10)
(1)The Hospital for Sick Children, Division of Gastroenterology Hepatology and Nutrition, Toronto, Canada;(2)Newcastle University, Gastroenterology, Newcastle upon Tyne, United Kingdom;(3)Newcastle Upon Tyne Hospitals NHS Foundation Trust, Gastroenterology, Newcastle upon Tyne, United Kingdom;(4)Torbay and South Devon NHS Foundation Trust, Gastroenterology, Torbay, United Kingdom;(5)University of Exeter, Gastroenterology, Exeter, United Kingdom;(6)Royal Devon and Exeter NHS Foundation Trust, Gastroenterology, Exeter, United Kingdom;(7)University of Calgary, Gastroenterology, Calgary, Canada;(8)Medical University of Vienna, Gastroenterology, Vienna, Austria;(9)University of Hull, Gastroenterology, Kingston upon Hull, United Kingdom;(10)Hull University Teaching Hospitals NHS Trust, Gastroenterology, Kingston Upon Hull, United Kingdom
N01: Does physical activity positively impact fatigue in individuals with Inflammatory Bowel Disease?ECCO'21 Virtual
Year: 2021
Authors: Farrell, D.(1);Bager, P.(2);Bredin, F.(3);Cairnes, V.(4);Forry, M.(5);Gilham, E.(3);Godwin, N.(5);Herdmangrant, R.(6);Ni Dhalaigh, D.(1);O' Shea, T.(7);Sugrue, K.(8);
(1)Munster Technological University, Department of Nursing and Healthcare Sciences, Tralee, Ireland;(2)Aarhus University Hospital, Department of Clinical Medicine - The Department of Hepatology and Gastroenterology, Aarhus, Denmark;(3)The Queen Elizabeth Hospital- NHS Foundation Trust, Department of Gastroenterology, Kings Lynn, United Kingdom;(4)Royal Devon and Exeter NHS Foundation Trust, Department of Gastroenterology, Exeter, United Kingdom;(5)Beaumont Hospital, Department of Gastroenterology, Dublin, Ireland;(6)Kingston Hospital NHS Foundation Trust, Research and Innovation Department, Kingston upon Thames, United Kingdom;(7)Munster Technological University, Department of Business, Tralee, Ireland;(8)Mercy University Hospital, Department of Gastroenterology, Cork, Ireland
N02: PREVIEW study: Factors associated with willingness to switch from intravenous to subcutaneous formulations of CT-P13 and vedolizumab in patients with Inflammatory Bowel Disease.ECCO'21 Virtual
Year: 2021
Authors: Asnong, K.(1);Hoefkens, E.(1);Lembrechts, N.(1);Van de Schoot, I.(1);Pouillon, L.(1);Bossuyt, P.(1);
(1)Imelda General Hospital Bonheiden, Imelda GI Clinical Research Center, Bonheiden, Belgium
N03: Information flow experiences during COVID-19 in IBD patients: a prospective observational studyECCO'21 Virtual
Year: 2021
Authors: Geens, P.(1);De Dycker, E.(1);Paps, A.(1);Lambrechts, T.(1);Sabino, J.(1);Ferrante, M.(1);Vermeire, S.(1);
(1)KU Leuven, gastro enterology, Leuven, Belgium
N04: Being an IBD Clinical Nurse Specialist in the UK National Health Service: Challenges, Stressors and Coping MechanismsECCO'21 Virtual
Year: 2021
Authors: Dibley, L.(1);Kemp, K.(2);Duncan, J.(3);Mason, I.(4);Lisa, Y.(5);
(1)University of Greenwich, Faculty of Education- Health and Human Sciences, London, United Kingdom;(2)Manchester Royal Infirmary, Department of Gastroenterology, Manchester, United Kingdom;(3)Takeda, Nurse Education, London, United Kingdom;(4)Royal Free London NHS Foundation Trust, Department of Gastroenterology, London, United Kingdom;(5)London North West University Healthcare NHS Trust, St Mark's Hospital- IBD Unit, London, United Kingdom
N05: A Systematic Review of Self-Management Intervention Study for Patients with Inflammatory Bowel DiseaseECCO'21 Virtual
Year: 2021
Authors: Lizawa, M.(1);Hirose, L.(1);Tairaka, A.(1);Maya, N.(2);
(1)Takeda Pharmaceutical Company Limited., Japan Medical Office, Tokyo, Japan;(2)Mukogawa Women’s University, School of Nursing, Hyogo, Japan
N06: Patient perspectives on the role of the IBD nurse and telemedicine during COVID-19 pandemic: results from a Belgian tertiary IBD unitECCO'21 Virtual
Year: 2021
Authors: Dewitte, G.(1);Geldof, J.(1,2);Truyens, M.(1,2);Lobaton, T.(1,2);
(1)UZ Gent, Gastro-enterology, Gent, Belgium;(2)Ghent University, IBD research unit – Gastroenterology- Department of Internal Medicine and Pediatrics, Ghent, Belgium
N07: a qualitative study of the impact of inflammatory bowel disease on partnersECCO'21 Virtual
Year: 2021
Authors: Thapwong, P.(1);Norton, C.(2);Terry, H.(3);Czuber-Dochan, W.(4);
(1)King's college London, Nursing faculty, London, United Kingdom;(2)King's college London, Nursing faculty- Adult nursing department, London, United Kingdom;(3)Crohn's and Colitis UK, Policy- Public Affairs and Research, London, United Kingdom;(4)King's college London, Nursing faculty- Adult nursing, London, United Kingdom
N08: Construction of an explanatory model for quality of life in outpatients with ulcerative colitisECCO'21 Virtual
Year: 2021
Authors: Takahashi, M.(1);Nunotani, M.(2);Aoyama, N.(3);
(1)Mukogawa Women’s University- Graduate School of Nursing, Department of nursing, Nishinomiya, Japan;(2)Mukogawa Women’s University, Department of nursing, Nishinomiya, Japan;(3)Aoyama Medical Clinic, Gastroenterologist, Kobe, Japan
N09: Sexuality as lived incompleteness: exploring intimacy and sexuality experiences of people living with inflammatory bowel diseaseECCO'21 Virtual
Year: 2021
Authors: Fourie, S.(1,2);Norton , C.(2);Jackson, D.(3);Czuber-Dochan , W.(2);
(1)University of Oxford, Nuffield Department of Medicine, Oxford, United Kingdom;(2)King's College London, Florence Nightingale Faculty of Nursing Midwifery and Palliative Care, London, United Kingdom;(3)University of Sydney, Nursing, Sydney, Australia; Simmons Group
N10: Experience with telemedicine during the COVID-19 pandemic and preferences for future e-health in a large IBD cohortECCO'21 Virtual
Year: 2021
Authors: Breiteneicher, S.(1);Le Thi, T.G.(2);Klucker, E.(2);Schwerd, T.(2);Csollarova, K.(1);Neuhaus, L.(1);Koletzko, S.(2);Török, H.(1);Koletzko, L.(1);
(1)LMU Klinikum Campus Großhadern, Medizinische Klinik und Poliklinik II, Munich, Germany;(2)Dr. von Hauner Children’s Hospital- LMU Klinikum, Department of Pediatrics, Munich, Germany